Sarah B. Goldberg
Yale University
109 Papers
450 Citations
Sarah B. Goldberg is an academic researcher from Yale University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 31, co-authored 105 publications. Previous affiliations of Sarah B. Goldberg include Yale Cancer Center.
Chat about Author
Papers
Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
Jacqulyne P. Robichaux,Yasir Elamin,Zhi Tan,Brett W. Carter,Shuxing Zhang,Shengwu Liu,Shuai Li,Ting Chen,Alissa Poteete,Adriana Estrada-Bernal,Anh T. Le,Anna Truini,Monique B. Nilsson,Huiying Sun,Emily Roarty,Sarah B. Goldberg,Julie R. Brahmer,Mehmet Altan,Charles Lu,Vassiliki A. Papadimitrakopoulou,Katerina Politi,Robert C. Doebele,Kwok-Kin Wong,John V. Heymach +23 more
TL;DR: These data identify poziotinib as a potent, clinically active inhibitor of EGFR and HER2 exon 20 mutations and illuminate the molecular features of TKIs that may circumvent steric changes induced by these mutations.
Melanoma brain metastasis pseudoprogression after pembrolizumab treatment
Justine V. Cohen,Ahmed K. Alomari,Alexander O. Vortmeyer,Lucia B. Jilaveanu,Sarah B. Goldberg,Amit Mahajan,Veronica Chiang,Harriet M. Kluger +7 more
TL;DR: A case of a patient with progressing brain metastases treated with a single cycle of pembrolizumab, who presented with mental status changes 11 days thereafter, documents pseudoprogression in brain metastase treated with antibodies to PD-1.
A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-Small Cell Lung Cancer
Kimberly L. Johung,Xiaopan Yao,Fangyong Li,James B. Yu,Scott N. Gettinger,Sarah B. Goldberg,Roy H. Decker,Judith Hess,Veronica Chiang,Joseph N. Contessa +9 more
TL;DR: This study suggests that EGFR kinase domain mutations and EML4-ALK translocations are radiosensitive NSCLC genotypes, and proposes a novel model to identify radiosensitive subtypes of NSCLc.
Multidisciplinary Management of Small Cell Lung Cancer
TL;DR: Prophylactic cranial irradiation reduces the development of brain metastases and prolongs survival in patients with both limited-stage and extensive-stage disease who have responded to chemotherapy.
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.
TL;DR: The biological rationale for targeting the PD-1 pathway with monoclonal antibodies for the treatment of cancer is described as a context for examining the results of early clinical trials and the landscape of ongoing clinical trials is surveyed.